Patients with HPV-positive oropharyngeal cancer may not require post-radiation surgery
the ONA take:
According to new findings presented at the American Society for Radiation Oncology's (ASTRO) 56th Annual Meeting in San Francisco, California, patients with human papillomavirus (HPV)-positive oropharyngeal cancer may not require neck surgery after receiving radiation therapy and chemotherapy.
In the study, researchers at Fox Chase Cancer Center in Philadelphia, Pennsylvania, analyzed the medical records of 396 patients with at least locally advanced oropharyngeal cancer. Of those, the records of 99 patients indicated whether or not their cancer had likely been activated by HPV, and 146 patients underwent neck surgery within 180 days after the completion of radiation therapy.
The researchers found that patients with HPV-positive oropharygneal cancer were most likely to respond better to treatment compared with those with HPV-negative cancer. This trend has also been seen in previous studies. Patients who were found to have a protein called p16, an indicator of HPV-positive cancer, were less likely to experience a recurrence of their cancer.
Patients with HPV-positive cancer who elected to undergo neck surgery were more likely to have benign bumps, while those uninfected by HPV who underwent neck surgery were more likely to have malignant bumps.
HPV-positive oropharyngeal cancer may not require surgery after receiving radiation and chemo.
A new study shows that patients with human papillomavirus (HPV) – the same virus associated with both cervical and head and neck cancer – positive oropharyngeal cancer see significantly higher rates of complete response on a post-radiation neck dissection than those with HPV-negative oropharyngeal cancer.
Fox Chase Cancer Center researchers presented the findings at the American Society for Radiation Oncology's 56th Annual Meeting on Wednesday, September 17.
Sign Up for Free e-newsletters
- Distress, Neuroticism Predict Long-term Emotional Distress After Cancer Diagnosis
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Patient Satisfaction Ratings Can Be Negatively Impacted by Nurse Staffing Ratio
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Bacteria in Probiotics Carry Potential Risks for Immunocompromised Patients
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- Overall Survival Prolonged With HIPEC + Cytoreductive Surgery for Gastric Cancer
- Better Postoperative Outcomes With RAMIE for Esophageal Cancer
- Distinct Patterns of Shiny White Streaks Strong Indicator of Melanoma
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|